Search

Your search keyword '"Singh, Ajeet B."' showing total 82 results
Start Over Author "Singh, Ajeet B."
82 results on '"Singh, Ajeet B."'

51. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary

Author

Malhi, Gin S, primary, Outhred, Tim, additional, Hamilton, Amber, additional, Boyce, Philip M, additional, Bryant, Richard, additional, Fitzgerald, Paul B, additional, Lyndon, Bill, additional, Mulder, Roger, additional, Murray, Greg, additional, Porter, Richard J, additional, Singh, Ajeet B, additional, and Fritz, Kristina, additional

Published
2018
Full Text
View/download PDF

54. Priorities in the assessment and management of perinatal mood disorders

Author

Boyce, Philip, primary, Lyndon, Bill, additional, Outhred, Tim, additional, Hamilton, Amber, additional, Morris, Grace, additional, Das, Pritha, additional, Bassett, Darryl, additional, Baune, Bernhard T, additional, Berk, Michael, additional, Mulder, Roger, additional, Parker, Gordon, additional, Singh, Ajeet B, additional, and Malhi, Gin S, additional

Published
2017
Full Text
View/download PDF

55. Defining disorders with permeable borders: you say bipolar, I say borderline!

Author

Bassett, Darryl, primary, Mulder, Roger, additional, Outhred, Tim, additional, Hamilton, Amber, additional, Morris, Grace, additional, Das, Pritha, additional, Berk, Michael, additional, Baune, Bernhard T, additional, Boyce, Philip, additional, Lyndon, Bill, additional, Parker, Gordon, additional, Singh, Ajeet B, additional, and Malhi, Gin S, additional

Published
2017
Full Text
View/download PDF

56. Is atypical depression simply a typical depression with unusual symptoms?

Author

Lyndon, Bill, primary, Parker, Gordon, additional, Morris, Grace, additional, Das, Pritha, additional, Outhred, Tim, additional, Hamilton, Amber, additional, Bassett, Darryl, additional, Baune, Bernhard T, additional, Berk, Michael, additional, Boyce, Philip, additional, Mulder, Roger, additional, Singh, Ajeet B, additional, and Malhi, Gin S, additional

Published
2017
Full Text
View/download PDF

57. The limitations of using randomised controlled trials as a basis for developing treatment guidelines

Author

Mulder, Roger, primary, Singh, Ajeet B, additional, Hamilton, Amber, additional, Das, Pritha, additional, Outhred, Tim, additional, Morris, Grace, additional, Bassett, Darryl, additional, Baune, Bernhard T, additional, Berk, Michael, additional, Boyce, Philip, additional, Lyndon, Bill, additional, Parker, Gordon, additional, and Malhi, Gin S, additional

Published
2017
Full Text
View/download PDF

58. Psychotropic pharmacogenetics – Distraction or destiny?

Author

Singh, Ajeet B, primary, Baune, Bernhard T, additional, Hamilton, Amber, additional, Das, Pritha, additional, Outhred, Tim, additional, Morris, Grace, additional, Bassett, Darryl, additional, Berk, Michael, additional, Boyce, Philip, additional, Lyndon, Bill, additional, Mulder, Roger, additional, Parker, Gordon, additional, and Malhi, Gin S, additional

Published
2017
Full Text
View/download PDF

59. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial

Author

Dean, Olivia M, primary, Kanchanatawan, Buranee, additional, Ashton, Melanie, additional, Mohebbi, Mohammadreza, additional, Ng, Chee Hong, additional, Maes, Michael, additional, Berk, Lesley, additional, Sughondhabirom, Atapol, additional, Tangwongchai, Sookjaroen, additional, Singh, Ajeet B, additional, McKenzie, Helen, additional, Smith, Deidre J, additional, Malhi, Gin S, additional, Dowling, Nathan, additional, and Berk, Michael, additional

Published
2017
Full Text
View/download PDF

60. Mixed mood: The not so united states?

Author

Malhi, Gin S, primary, Berk, Michael, additional, Morris, Grace, additional, Hamilton, Amber, additional, Outhred, Tim, additional, Das, Pritha, additional, Bassett, Darryl, additional, Baune, Bernhard T, additional, Boyce, Philip, additional, Lyndon, Bill, additional, Mulder, Roger, additional, Parker, Gordon, additional, and Singh, Ajeet B, additional

Published
2017
Full Text
View/download PDF

61. Defining melancholia: A core mood disorder

Author

Parker, Gordon, primary, Bassett, Darryl, additional, Outhred, Tim, additional, Morris, Grace, additional, Hamilton, Amber, additional, Das, Pritha, additional, Baune, Bernhard T, additional, Berk, Michael, additional, Boyce, Philip, additional, Lyndon, Bill, additional, Mulder, Roger, additional, Singh, Ajeet B, additional, and Malhi, Gin S, additional

Published
2017
Full Text
View/download PDF

63. Tech giants enter mental health

Author

Eyre, Harris A., Singh, Ajeet B., Reynolds III, Charles, Eyre, Harris A., Singh, Ajeet B., and Reynolds III, Charles

Published
2016

64. Mental health system development in Asia: does Australia have a role?

Author

Arandjelovic, Katarina, Eyre, Harris A., Forbes, Malcolm P., Bauer, Renee, Aggarwal, Shilpa, Singh, Ajeet B., Baune, Bernhard T., Everall, Ian, Berk, Michael, Ng, Chee, Arandjelovic, Katarina, Eyre, Harris A., Forbes, Malcolm P., Bauer, Renee, Aggarwal, Shilpa, Singh, Ajeet B., Baune, Bernhard T., Everall, Ian, Berk, Michael, and Ng, Chee

Abstract

BACKGROUND: Socioeconomic trends herald what many describe as the Asian Century, whereby Asian economic, political and cultural influence is in global ascendency. Broadening relevant ties between Australia and Asia is evident and logical and may include strengthening alliances in mental health systems. AIM: We argue the importance of strengthening Asian mental health systems and some of the roles Australian mental health workers could have in promoting strengthening the Asian mental health system. METHODS: This paper is a narrative review which sources data from reputable search databases. RESULTS: A well-articulated Australian strategy to support strengthening the mental health system in Asia is lacking. While there are active initiatives operating in this space, these remain fragmented and underdeveloped. Coordinated, collaborative and culturally respectful efforts to enhance health education, research, policy, leadership and development assistance are key opportunities. CONCLUSION: Psychiatrists and other mental health professionals have a unique opportunity to contribute to improved mental health outcomes in Asia.

Published
2016

75. Treatment of bipolar depression

Author

Berk, Michael, primary, Berk, Lesley, additional, Davey, Christopher G, additional, Moylan, Steven, additional, Giorlando, Francesco, additional, Singh, Ajeet B, additional, Kalra, Harish, additional, Dodd, Seetal, additional, and Malhi, Gin S, additional

Published
2013
Full Text
View/download PDF

77. Treatment of bipolar depression

Author

Berk, Michael, primary, Berk, Lesley, additional, Davey, Christopher G, additional, Moylan, Steven, additional, Giorlando, Francesco, additional, Singh, Ajeet B, additional, Kalra, Harish, additional, Dodd, Seetal, additional, and Malhi, Gin S, additional

Published
2012
Full Text
View/download PDF

78. The limitations of using randomised controlled trials as a basis for developing treatment guidelines.

Author

Mulder, Roger, Singh, Ajeet B., Hamilton, Amber, Das, Pritha, Outhred, Tim, Morris, Grace, Bassett, Darryl, Baune, Bernhard T., Berk, Michael, Boyce, Philip, Lyndon, Bill, Parker, Gordon, and Malhi, Gin S.

Subjects
CONSORTIA, MEDICAL protocols, DECISION making in clinical medicine, RANDOMIZED controlled trials
Abstract

Randomised controlled trials (RCTs) are considered the 'gold standard' by which novel psychotropic medications and psychological interventions are evaluated and consequently adopted into widespread clinical practice. However, there are some limitations to using RCTs as the basis for developing treatment guidelines. While RCTs allow researchers to determine whether a given medication or intervention is effective in a specific patient sample, for practicing clinicians it is more important to know whether it will work for their particular patient in their particular setting. This information cannot be garnered from an RCT. These inherent limitations are exacerbated by biases in design, recruitment, sample populations and data analysis that are inevitable in real-world studies. While trial registration and CONSORT have been implemented to correct and improve these issues, it is worrying that many trials fail to achieve such standards and yet their findings are used to inform clinical decision making. This perspective piece questions the assumptions of RCTs and highlights the widespread distortion of findings that currently undermine the credibility of this powerful design. It is recommended that the clinical guidelines include advice as to what should be considered good and relevant evidence and that external bodies continue to monitor RCTs to ensure that the outcomes published indeed reflect reality [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

79. Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies

Author

Ghanizadeh, Ahmad, Singh, Ajeet B, Berk, Michael, and Torabi-Nami, Mohammad

Abstract

Introduction:Homocysteine levels have been associated with major depression, but associations with bipolar disorder remain less clear. Some data suggest homocysteine levels have potential as a biomarker of treatment response; however the literature is mixed.Areas covered:Oxidized forms of homocysteine can be potentially neurotoxic leading to glutamate toxicity, apoptotic transformation and neurodegenerative processes. High homocysteine may be a risk biomarker for bipolar disorders, but the empirical base remains too weak for firm conclusions. This review discusses the current literature for homocysteine levels as a biomarker.Expert opinion:It is premature to foreclose the utility of homocysteine levels as a biomarker for bipolar disorder due the methodological inadequacies in the existing literature. These methodological design issues include lack of control for the confounding variables of concurrent medication, phase of bipolar disorder, gender, age, nutritional status, thyroid, liver and renal function, smoking or lean body mass. Well-powered association studies with confounder control could help shed more light on the important clinical question of homocysteine’s utility as a biomarker in bipolar disorder. Future experiments are needed to examine the outcome of interventions modulating homocysteine for treating bipolar disorder. Only prospective randomized control trials will provide definitive evidence of the utility of homocysteine as a biomarker or therapeutic target.

Published
2015
Full Text
View/download PDF

80. Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response

Author

Walker, Adam J., Mohebbi, Mohammadreza, Maes, Michael, Berk, Michael, Walder, Ken, Bortolasci, Chiara C., Liu, Zoe SJ., Ng, Chee H., Ashton, Melanie M., Berk, Lesley, Singh, Ajeet B., Malhi, Gin S., and Dean, Olivia M.

Abstract

Adjunctive minocycline shows promise in treating affective and psychotic disorders; however, the therapeutic mechanism remains unclear. Identifying relevant biomarkers may enhance the efficacy of novel adjunctive treatment candidates. We thus investigated the peripheral immune-inflammatory profile in a randomized controlled trial (RCT) of minocycline in major depressive disorder (MDD).

Published
2022
Full Text
View/download PDF

81. Atypical antipsychotic agents; Peas in a pod or chalk and cheese?

Author

Singh, Ajeet B, Nierenberg, Andrew A, Yatham, Lakshmi N, and Berk, Michael

Subjects
3. Good health
Abstract

With escalating health expenditure and a shrinking purse, there is increased focus on the cost efficacy of still patented versus generic medications in general, and for atypical antipsychotics in particular. In a recent BMC Medicine article, Godman and colleagues presented data indicating poor uptake of the off patent atypical antipsychotic risperidone, arguing for authorities to mandate its greater use. This is under the assumption of clinical equivalence of atypical antipsychotics. This commentary argues that there are clinically meaningful differences between atypical antipsychotics and important inter-individual heterogeneity in clinical response and tolerability. Access to a broad range of atypical antipsychotics enables clinicians to tailor care, taking consideration of differential efficacy and adverse effects profile in order to meet the needs of individual patients with improved real world effectiveness of treatment. Restriction of agent choice risks detracting from optimal clinical care, with possible poorer outcomes and greater costs of care. A balance between encouraging use of cheapest in class agent and allowing access to various atypical agents for tailored care is likely to produce optimal health outcomes. Please see related article: http://www.biomedcentral.com/1741-7015/12/98 .

82. Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial.

Author

Kavanagh BE, Williams LJ, Berk M, Turner A, Jackson HJ, Mohebbi M, Kanchanatawan B, Ashton MM, Ng CH, Maes M, Berk L, Malhi GS, Dowling N, Singh AB, and Dean OM

Subjects
Adult, Aged, Comorbidity, Double-Blind Method, Female, Humans, Male, Middle Aged, Personal Satisfaction, Personality Tests, Placebo Effect, Psychiatric Status Rating Scales, Quality of Life, Self Report, Treatment Outcome, Antidepressive Agents administration & dosage, Depressive Disorder, Major drug therapy, Depressive Disorder, Major psychology, Minocycline administration & dosage, Personality Disorders psychology
Abstract

Objective: This study aimed to determine if personality disorder (PD) predicted functional outcomes in patients with major depressive disorder (MDD)., Methods: Data (n=71) from a double-blind, randomized, placebo-controlled 12-week trial assessing the efficacy of 200 mg/day adjunctive minocycline for MDD were examined. PD was measured using the Standardized Assessment of Personality Abbreviated Scale. Outcome measures included Clinical Global Impression - Improvement (CGI-I), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), Social and Occupational Functioning Scale (SOFAS), and Range of Impaired Functioning (RIFT). Analysis of covariance was used to examine the impact of PD (dichotomized factor [≥ 3] or continuous measure) on the outcome measures-treatment group correlation., Results: PD was identified in 69% of the sample. After adjusting for age, sex, and baseline scores for each of the outcome measures, there was no significant difference between participants with and without PD on week 12 scores for any of the outcome measures (all p > 0.14)., Conclusion: In this secondary analysis of a primary efficacy study, PD was a common comorbidity among those with MDD, but was not a significant predictor of functional outcomes. This study adds to the limited literature on PD in randomized controlled trials for MDD., Clinical Trial Registration: ACTRN12612000283875.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results